|Table of Contents|

Pep-1-guided PDA loaded temozolomide nanoparticles for chemotherapy and photothermal double combination therapy of glioblastoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 15
Page:
2789-2798
Research Field:
Publishing date:

Info

Title:
Pep-1-guided PDA loaded temozolomide nanoparticles for chemotherapy and photothermal double combination therapy of glioblastoma
Author(s):
WU Hao1; 2; LIU Qi3; WEI Min1; 2; MA Qiang2; LI Yuping2; ZHANG Hengzhu2
1.Graduate School of Dalian Medical University,Liaoning Dalian 116044,China;2.Department of Neurosurgery,Clinical Medical College,Yangzhou University,Jiangsu Yangzhou 225001,China;3.Department of Neurosurgery,The First Hospital of Yulin Suide Branch,Shaanxi Yulin 718000,China.
Keywords:
temozolomide; polydopamine; Pep-1; glioblastoma; Nano-drug delivery system; combination therapy
PACS:
R730.261
DOI:
10.3969/j.issn.1672-4992.2023.15.006
Abstract:
Objective:To construct Pep-1-guided polydopamine-loaded temozolomide nanoparticles for chemotherapy and photothermal double combination therapy of glioblastoma.Methods:The Schiff base reaction and self-assembly of the active groups of PDA,such as catechol,amino group and carboxyl group,with the carbonyl group,amino group and sulfhydryl group of TMZ and Pep-1,were carried out to obtain Pep-1@PDA-TMZ NPs.The size,charge and morphology of these groups were characterized by dynamic light scattering and transmission electron microscopy.Fourier infrared spectrum and ultraviolet spectrum were used to analyze the loading and assembly of the drug.Water and fetal bovine serum were used to investigate its stability.The near infrared thermal imager was used to verify the photothermal conversion efficiency.And examine the release of TMZ.Cell experiments were conducted to verify the biocompatibility and uptake of Pep-1@PDA NPs and the inhibition rate of Pep-1@PDA-TMZ NPs on U87 and C6 cells.Results:The prepared Pep-1@PDA-TMZ NPs was spherical with a size of about 140 nm and a drug loading of about 50%.Endocytosis imaging showed that the phagocytosis of Pep-1@PDA-TMZ NPs by U87 and C6 cells was higher than PDA-TMZ NPs.Under 808 nm laser irradiation,Pep-1@PDA-TMZ NPs inhibited U87 and C6 cells by 90.81% and 82.29%,respectively(P＜0.05).Conclusion:The nano drug delivery system Pep-1@PDA-TMZ NPs has high drug loading rate,strong penetration,good biocompatibility and targeting,and can provide chemotherapy and phototherapy as one of the dual therapeutic effects,which is expected to be gradually transformed into clinical research.

References:

[1]OSTROM QT,PATIL N,CIOFFI G,et al.CBTRUS statistical report:Primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017 ［J］.Neuro Oncol,2020,22(12 Suppl 2):iv1-iv96.
[2]LI J,FENG L,LU Y.Glioblastoma multiforme:Diagnosis,treatment,and invasion［J］.Biomed Res,2022,37(1):47-58.
[3]LAKSHMI BA,KIM YJ.Modernistic and emerging developments of nanotechnology in glioblastoma-targeted theranostic applications［J］.Int J Mol Sci,2022,23(3):1641.
[4]HELWEG LP,STORM J,WITTE KE,et al.Targeting sky signaling pathways in glioblastoma stem cells for the development of efficient chemo- and immunotherapy［J］.Int J Mol Sci,2022,23(21):12919.
[5]WANG L,TANG S,YU Y,et al.Intranasal delivery of temozolomide-conjugated gold nanoparticles functionalized with anti-EphA3 for glioblastoma targeting［J］.Mol Pharm,2021,18(3):915-927.
[6]MAREI HE.Multimodal targeting of glioma with functionalized nanoparticles［J］.Cancer Cell Int,2022,22(1):265.
[7]YU Y,WANG A,WANG S,et al.Efficacy of temozolomide-conjugated gold nanoparticle photothermal therapy of drug-resistant glioblastoma and its mechanism study［J］.Mol Pharm,2022,19(4):1219-1229.
[8]WANG Y,JIANG Y,WEI D,et al.Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance［J］.Nat Biomed Eng,2021,5(9):1048-1058.
[9]TSAI CY,KO HJ,CHIOU SJ,et al.NBM-BMX,an HDAC8 inhibitor,overcomes temozolomide resistance in glioblastoma multiforme by downregulating the β-Catenin/c-Myc/SOX2 pathway and upregulating p53-mediated MGMT inhibition［J］.Int J Mol Sci,2021,22(11):5907.
[10]MA Y,WANG C,ZHU L,et al.Polydopamine-drug conjugate nanocomposites based on ZIF-8 for targeted cancer photothermal-chemotherapy［J］.J Biomed Mater Res A,2022,110(4):954-963.
[11]GHOSH G,BARMAN R,MUKHERJEE A,et al.Control over multiple Nano-and secondary structures in peptide self-assembly［J］.Angew Chem Int Ed Engl,2022,61(5):e202113403.
[12]LIU Y,HUANG J,LIU J.Single laser activated photothermal/photodynamic dual-modal cancer phototherapy by using ROS-responsive targeting flower-like ruthenium nanoparticles［J］.J Mater Chem B,2022,10(38):7760-7771.
[13]LIMA-SOUSA R,ALVES CG,MELO BL,et al.Poly(2-ethyl-2-oxazoline) functionalized reduced graphene oxide:Optimization of the reduction process using dopamine and application in cancer photothermal therapy［J］.Mater Sci Eng C Mater Biol Appl,2021,130:112468.
[14]LI H,YIN D,LI W,et al.Polydopamine-based nanomaterials and their potentials in advanced drug delivery and therapy［J］.Colloids Surf B Biointerfaces,2021,199:111502.
[15]WANG L,ZHANG T,XING Y,et al.Interfacially responsive electron transfer and matter conversion by polydopamine-mediated nanoplatforms for advancing disease theranostics［J］.Wiley Interdiscip Rev Nanomed Nanobiotechnol,2022,14(5):e1805.
[16]LIU Y,CHOI CKK,HONG H,et al.Dopamine receptor-mediated binding and cellular uptake of polydopamine-coated nanoparticles［J］.ACS Nano,2021,15(8):13871-13890.
[17]DAI G,CHOI CKK,CHOI CHJ,et al.Glutathione-degradable polydopamine nanoparticles as a versatile platform for fabrication of advanced photosensitisers for anticancer therapy［J］.Biomater Sci,2021,10(1):189-201.
[18]SU M,CHEN Y,JIA L,et al.Camptothecin-loaded and manganese dioxide-coated polydopamine nanomedicine used for magnetic resonance imaging diagnosis and chemo-photothermal therapy for Lung Cancer［J］.Int J Nanomedicine,2022,17:6687-6705.
[19]ZHOU M,ZOU X,CHENG K,et al.The role of cell-penetrating peptides in potential anti-cancer therapy［J］.Clin Transl Med,2022,12(5):e822.
[20]KOO JH,KIM GR,NAM KH,et al.Unleashing cell-penetrating peptide applications for immunotherapy［J］.Trends Mol Med,2022,28(6):482-496.
[21]ALGHAMRI MS,BANERJEE K,MUJEEB AA,et al.Systemic delivery of an adjuvant CXCR4-CXCL12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapy［J］.ACS Nano,2022,16(6):8729-8750.
[22]LI CM,HARATIPOUR P,LINGEMAN RG,et al.Novel peptide therapeutic approaches for cancer treatment［J］.Cells,2021,10(11):2908.
[23]ZORKO M,JONES S,LANGEL U.Cell-penetrating peptides in protein mimicry and cancer therapeutics［J］.Adv Drug Deliv Rev,2022,180:114044.
[24]GUO X,WU G,WANG H,et al.Pep-1 & borneol-bifunctionalized carmustine-loaded micelles enhance anti-glioma efficacy through tumor-targeting and BBB-penetrating［J］.J Pharm Sci,2019,108(5):1726-1735.
[25]CHOI YJ,KIM DW,SHIN MJ,et al.PEP-1-GLRX1 reduces dopaminergic neuronal cell loss by modulating MAPK and apoptosis signaling in parkinson's disease［J］.Molecules,2021,26(11):3329.
[26]WANG T,WANG C,ZHENG S,et al.Insight into the mechanism of internalization of the cell-penetrating carrier peptide pep-1 by conformational analysis［J］.J Biomed Nanotechnol,2020,16(7):1135-1143.
[27]JIAO Z,LI Y,PANG H,et al.Pep-1 peptide-functionalized liposome to enhance the anticancer efficacy of cilengitide in glioma treatment［J］.Colloids Surf B Biointerfaces,2017,158:68-75.
[28]LUGANI S,HALABI EA,OH J,et al.Dual immunostimulatory pathway agonism through a synthetic nanocarrier triggers robust anti-tumor immunity in murine glioblastoma［J］.Adv Mater,2023,35(7):e2208782.
[29]LIN XM,SHI XX,XIONG L,et al.Construction of IL-13 receptor α2-targeting resveratrol nanoparticles against glioblastoma cells:Therapeutic efficacy and molecular effects［J］.Int J Mol Sci,2021,22(19):10622.
[30]XU C,BAI Y,AN Z,et al.IL-13Rα2 humanized scFv-based CAR-T cells exhibit therapeutic activity against glioblastoma［J］.Mol Ther Oncolytics,2022,24:443-451.
[31]BARZEGAR BEHROOZ A,TALAIE Z,SYAHIR A.Nanotechnology-based combinatorial anti-glioblastoma therapies:Moving from terminal to treatable［J］.Pharmaceutics,2022,14(8):1697.
[32]ORTIZ N,VASQUEZ PA,VIDAL F,et al.Polyamidoamine-based nanovector for the efficient delivery of methotrexate to U87 glioma cells［J］.Nanomedicine(Lond),2020,15(28):2771-2784.
[33]LIANG R,WU C,LIU S,et al.Targeting interleukin-13 receptor α2(IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers［J］.Drug Deliv,2022,29(1):1620-1630.
[34]SAKAMOTO K,MORISHITA T,ABURAI K,et al.Direct entry of cell-penetrating peptide can be controlled by maneuvering the membrane curvature［J］.Sci Rep,2021,11(1):31.
[35]KIM H,KITAMATSU M,OHTSUKI T.Enhanced intracellular peptide delivery by multivalent cell-penetrating peptide with bioreducible linkage［J］.Bioorg Med Chem Lett,2018,28(3):378-381.
[36]ZHAO L,CHEN H,LU L,et al.Design and screening of a novel neuropilin-1 targeted penetrating peptide for anti-angiogenic therapy in glioma［J］.Life Sci,2021,270:119113.
[37]LI L,CHEN J,MING Y,et al.The application of peptides in glioma:A novel tool for therapy［J］.Curr Pharm Biotechnol,2022,23(5):620-633.
[38]EL-GAMAL FR,AKL MA,MOWAFY HA,et al.Synthesis and evaluation of high functionality and quality cell-penetrating peptide conjugated lipid for octaarginine modified PEGylated liposomes in U251 and U87 glioma cells［J］.J Pharm Sci,2022,111(6):1719-1727.
[39]BASSEREAU P.Concluding remarks:peptide-membrane interactions［J］.Faraday Discuss,2021,232(0):482-493.
[40]MITCHELL CJ,JOHNSON TS,DEBER CM.Transmembrane peptide effects on bacterial membrane integrity and organization［J］.Biophys J,2022,121(17):3253-3262.
[41]KURIHARA R,HORIBE T,SHIMIZU E,et al.A novel interleukin-13 receptor alpha 2-targeted hybrid peptide for effective glioblastoma therapy［J］.Chem Biol Drug Des,2019,94(1):1402-1413.
[42]BROWN CE,RODRIGUEZ A,PALMER J,et al.Off-the-shelf,steroid-resistant,IL13Rα2-specificCART cells for treatment of glioblastoma［J］.Neuro Oncol,2022,24(8):1318-1330.
[43]KNUDSONKM,HWANGS,MCCANNMS,et al.Recent advances in IL-13Rα2-directed cancer immunotherapy［J］.Front Immunol,2022,13:878365.
[44]RECHBERGER JS,PORATH KA,ZHANG L,et al.IL-13Rα2 status predicts GB-13(IL13.E13K-PE4E) efficacy in high-grade glioma［J］.Pharmaceutics,2022,14(5):922.
[45]HAN J,PURI RK.Analysis of the cancer genome atlas(TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme［J］.J Neurooncol,2018,136(3):463-474.
[46]KIM K,GWAK HS,HAN N,et al.Chimeric antigen receptor T cells with modified interleukin-13 preferentially recognize IL13Rα2 and suppress malignant glioma:A preclinical study［J］.Front Immunol,2021,12:715000.
[47]DU Y,CHEN Z,DUAN X,et al.99Tcm-labeled peptide targeting interleukin 13 receptor α 2 for tumor imaging in a cervical cancer mouse model［J］.Ann Nucl Med,2022,36(4):360-372.
[48]NELKE C,SPATOLA M,SCHROETER CB,et al.Neonatal Fc receptor-targeted therapies in neurology［J］.Neurotherapeutics,2022,19(3):729-740.
[49]WANG B,WU W,LU H,et al.Enhanced anti-tumor of Pep-1 modified superparamagnetic iron oxide/PTX loaded polymer nanoparticles［J］.Front Pharmacol,2019,9:1556.
[50]LIN XM,SHI XX,XIONG L,et al.Construction of IL-13 receptor α2-targeting resveratrol nanoparticles against glioblastoma cells:Therapeutic efficacy and molecular effects［J］.Int J Mol Sci,2021,22(19):10622.
[51]SABIR F,ISMAIL R,CSOKA I.Nose-to-brain delivery of antiglioblastoma drugs embedded into lipid nanocarrier systems:status quo and outlook［J］.Drug Discov Today,2020,25(1):185-194.

Memo

Memo:
National Natural Science Foundation of China（No.82172603）;国家自然科学基金(编号：82172603)
Last Update: 2023-06-30